Monika J Dziuba: The Role of Organoids in Precision Medicine
J Dziuba, Director at shared a post on LinkedIn:
“Organoids are emerging as powerful preclinical models in oncology R&D, with the potential to improve prediction and reduce translational risk.
In our recent Behind the Breakthroughs episode, Kate Sasser PhD, Chief CSO at Tempus AI shared insights into how Tempus uses AI to analyze unstructured clinical data to develop patient-derived organoid models for therapeutic refinement. Most exciting is the vision of an interconnected “lab-in-a-loop” system – a cycle of real-world data, biological modeling, and AI analysis.
Our white paper offers insights on the scientific landscape, adoption barriers, and how pharma companies are using organoids to advance precision medicine. Download the full white paper here.”
More posts featuring Precision Oncology on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023